ALSA Ventures Launches Vantage Biosciences
Vantage Biosciences, a new company launched by ALSA Ventures which invests in novel therapeutics for unmet medical needs, has announced the acquisition of lead asset VX-01, an oral therapy targeting diabetic eye diseases, set to enter Phase 2 clinical development in mid-2024.
The initial Phase 2 trial aims to begin enrolling participants by mid-2024 and will focus on individuals in the early stages of diabetes for treatment.
Diabetic eye disease is the main cause of blindness in working age people and affects 1 in 3 people with diabetes – more than 382 million people worldwide. It typically develops 5-6 years after diabetes onset.
“We are excited to launch Vantage Biosciences and progress VX-01 into Phase 2 trials with the promise to provide a significant advance in an area of unmet need for the treatment of diabetic eye diseases,” commented Alek Safarian, ALSA Ventures’ Managing Partner.
Source
